Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

Study Of An FDA-approved Drug As Additional Therapy In Patients With Schizophrenia

ClinicalTrials.gov ID: NCT00086593

Public ClinicalTrials.gov record NCT00086593. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jun 26, 2026, 2:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Randomized, Double-Blind, Parallel Group Study to Evaluate the Efficacy and Safety of a Flexible Dose of Lamotrigine Compared to Placebo as an Adjunctive Therapy to an Atypical Antipsychotic Agent(s) in Subjects With Schizophrenia

Study identification

NCT ID
NCT00086593
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
209 participants

Conditions and interventions

Conditions

Interventions

  • lamotrigine Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 65 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 30, 2004
Primary completion
Jun 30, 2005
Completion
Jun 30, 2005
Last update posted
Oct 6, 2016

2004 – 2005

United States locations

U.S. sites
21
U.S. states
9
U.S. cities
20
Facility City State ZIP Site status
GSK Investigational Site Little Rock Arkansas 72201
GSK Investigational Site Garden Grove California 92845
GSK Investigational Site Glendale California 91206
GSK Investigational Site Los Angeles California 90033
GSK Investigational Site Pico Rivera California 90660
GSK Investigational Site San Diego California 92126
GSK Investigational Site Sherman Oaks California 91403
GSK Investigational Site Coral Springs Florida 33065
GSK Investigational Site Maitland Florida 32751
GSK Investigational Site Miami Florida 33125
GSK Investigational Site North Miami Florida 33161
GSK Investigational Site Winter Park Florida 32789
GSK Investigational Site Niles Illinois 60714
GSK Investigational Site Oak Brook Illinois 60523
GSK Investigational Site Indianapolis Indiana 46202-5200
GSK Investigational Site Indianapolis Indiana 46202
GSK Investigational Site Staten Island New York 10305
GSK Investigational Site Nashville Tennessee 37203
GSK Investigational Site Bellaire Texas 77401
GSK Investigational Site San Antonio Texas 78229
GSK Investigational Site Madison Wisconsin 53711-2027

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 18 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00086593, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 6, 2016 · Synced Jun 26, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00086593 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →